{{위키데이터 속성 추적}}
{{Drugbox
| verifiedrevid = 458298378
| IUPAC_name = (2''S'',5''R'',6''R'')-6-{[3-(2,6-dichlorophenyl)-5-methyl-<br />oxazole-4-carbonyl]amino}-3,3-dimethyl-7-oxo-4-thia-<br />1-azabicyclo[3.2.0]heptane-2-carboxylic acid
| image = Dicloxacillin.svg
| image2 = Dicloxacillin-based-on-xtal-3D-bs-17.png
<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|monograph|dicloxacillin-sodium}}
| MedlinePlus = a685017
| pregnancy_AU = B2
| pregnancy_US = B
| legal_AU = S4
| legal_US = Rx-only
| routes_of_administration = [[경구 투여]]
<!--Pharmacokinetic data-->
| bioavailability = 60~80%
| protein_bound = 98%
| metabolism = [[간]]
| elimination_half-life = 0.7시간
| excretion = [[콩팥]], [[담도]]
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 3116-76-5
| ATC_prefix = J01
| ATC_suffix = CF01
| ATC_supplemental =  {{ATCvet|J51|CF01}}
| PubChem = 18381
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00485
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 17358
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = COF19H7WBK
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D02348
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 4511
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 893
<!--Chemical data-->
| C=19 | H=17 | Cl=2 | N=3 | O=5 | S=1
| SMILES = O=C(O)[C@@H]3N4C(=O)[C@@H](NC(=O)c2c(onc2c1c(Cl)cccc1Cl)C)[C@H]4SC3(C)C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C19H17Cl2N3O5S/c1-7-10(12(23-29-7)11-8(20)5-4-6-9(11)21)15(25)22-13-16(26)24-14(18(27)28)19(2,3)30-17(13)24/h4-6,13-14,17H,1-3H3,(H,22,25)(H,27,28)/t13-,14+,17-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = YFAGHNZHGGCZAX-JKIFEVAISA-N
}}
'''디클록사실린'''(Dicloxacillin)은 [[베타-락탐 계열 항생제]], 그중에서도 [[페니실린]] 계열에 속하는 [[좁은범위 항생제]]이다.<ref name=":0" /> 감수성이 있는 [[그람 양성균]] 치료에 사용된다.<ref name=":0">Product Information: DICLOXACILLIN SODIUM-dicloxacillin sodium capsule. Teva Pharmaceuticals USA Inc, Revised 8/2015</ref> 대다수 다른 페니실린에 내성을 가지는 [[황색포도상구균]] 등, [[베타-락타메이스]]를 만드는 세균에 활성을 보인다. 디클로실(Diclocil, [[브리스톨 마이어스 스퀴브|BMS]]) 등의 상품명으로 시판되어 있다.<ref>{{저널 인용| vauthors = Miranda-Novales G, Leaños-Miranda BE, Vilchis-Pérez M, Solórzano-Santos F | title = In vitro activity effects of combinations of cephalothin, dicloxacillin, imipenem, vancomycin and amikacin against methicillin-resistant Staphylococcus spp. strains | journal = Annals of Clinical Microbiology and Antimicrobials | volume = 5 | pages = 25 | date = October 2006 | pmid = 17034644 | pmc = 1617116 | doi = 10.1186/1476-0711-5-25 | doi-access = free }}</ref>

<!-- Society and culture -->특허 출원은 1961년, 의학용 사용 승인은 1968년에 이루어졌다.<ref name="Fis2006">{{서적 인용| vauthors = Fischer J, Ganellin CR |title=Analogue-based Drug Discovery |date=2006 |publisher=John Wiley & Sons |isbn=9783527607495 |page=491 |url=https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA491 }}</ref> [[복제약]]으로 이용 가능하다.<ref>{{웹 인용| title=Competitive Generic Therapy Approvals | website=U.S. [[Food and Drug Administration]] (FDA) | date=29 June 2023 | url=https://www.fda.gov/drugs/generic-drugs/competitive-generic-therapy-approvals | access-date=29 June 2023 | archive-date=29 June 2023 | archive-url=https://web.archive.org/web/20230629233651/https://www.fda.gov/drugs/generic-drugs/competitive-generic-therapy-approvals | url-status=live }}</ref>

== 각주 ==
{{각주}}

{{토막글|의학}}
[[분류:페니실린]]
[[분류:아이소옥사졸]]